RecruitingChronic Migraine
Investigation and Modulation of the Central Mu-Opioid Mechanism in Migraine (in Vivo)
Eligible age
18–65 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study investigates whether unilateral and bilateral non-invasive brain stimulation, given for 20 minutes/once per day for twenty days (M-F) can reduce migraine pain. Fourty patients will receive treatment (20 unilateral treatment, and 20 bilateral treatment), while twenty will receive a "sham" procedure. Another 20 Episodic Migraine patients will be recruited for the observational aim of the study which does not include brain stimulation.
Sponsor: University of Michigan
You may qualify if…
- ✓ Male or female, aged 18 to 65 (inclusive)
- ✓ Patients must have Episodic migraines that started before the age of 50, and currently experience:
- ✓ Chronic migraine (ICHD-3-beta), headache occurring on 15 days/month for more than six months, which, on at least eight days/month, has the features of a migraine headache.
- ✓ Episodic migraine (low frequency), specifically those with headache occurring less than 8 days/month.
- ✓ Willing to limit the introduction of new treatments and medications during the study period.
You may not qualify if…
- ✕ Significantly greater pain in body sites other than the head
- ✕ Active, untreated major concurrent systemic illness other than migraine
- ✕ Medical conditions that can impair health status independent of migraine (including cardiopulmonary disorders, malignancy, uncontrolled endocrine or allergies)
- ✕ Systemic rheumatic disorders (i.e., rheumatoid arthritis, systemic lupus erythematosus, gout, and fibromyalgia);
- ✕ History or current evidence of a psychotic disorder (e.g., bipolar disorder, schizophrenia) or severe major depression, as evidenced by Beck Depression score of \>30\*
- ✕ History of neurological disorder (e.g., epilepsy, stroke, neuropathy, neuropathic pain)
- ✕ Medication overuse headache (ICHD-3), regular intake for ≥10 days per month of ergotamine, triptans, combination analgesics, or any combination thereof OR ≥15 days per month of simple analgesics (acetaminophen, aspirin, NSAID), for more than 3 months
- ✕ Current use of opioid or dopaminergic drugs (or use within the last 3 months) or substance abuse (self-reported)
Where it's recruiting
Michigan
Ann Arbor
Source: ClinicalTrials.gov · NCT05769348 · last updated 2026-02-25